Middle East & Africa Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The therapeutic vaccines market in the Middle East and Africa (MEA) is projected to grow significantly, reaching approximately US$ 4,471.70 thousand by 2031, up from US$ 2,358.36 thousand in 2024, with a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031. This growth is primarily driven by heightened awareness of chronic and infectious diseases, including cancer, HIV, and hepatitis. Governments in the region are increasingly investing in healthcare infrastructure, while international collaborations are enhancing research and development efforts. However, challenges such as limited access to advanced medical technologies and high costs associated with vaccine development persist.

Countries like South Africa, Saudi Arabia, and the UAE are becoming central to this market due to their expanding biotech sectors and supportive health policies. The rising incidence of non-communicable diseases and a trend towards personalized medicine are also fueling demand for targeted immunotherapies. Although the MEA therapeutic vaccines market is still in its nascent stages compared to Western markets, it offers substantial long-term opportunities for stakeholders involved in the development and distribution of therapeutic vaccines, especially as regulatory frameworks and healthcare access improve.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented by product, technology, and end user.

By Product: The market is divided into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines dominating the market in 2024.
By End User: The end users include hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The development of vaccines for emerging pathogens that could lead to pandemics is challenging with traditional technologies. Therefore, there is a pressing need for innovative platforms that can quickly respond to pandemic threats and adapt to emerging variants. New vaccine technologies, such as mRNA vaccines, immuno-material-based technologies, nano-drug delivery systems, and viral vector-based vaccines, are transforming the landscape of therapeutic vaccine development. The success of mRNA COVID-19 vaccines illustrates the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These advanced platforms enable faster, more flexible, and scalable vaccine production, expediting the development of new therapeutic vaccines.

Research teams, such as those at the Wyss Institute at Harvard University, are pioneering novel vaccine platforms like OMNIVAX, which aims to create safe and effective therapeutic and prophylactic vaccines against various infections. OMNIVAX vaccines work by establishing a scaffold that attracts dendritic immune cells, programming them to target specific antigens, thus initiating a robust immune response.

Additionally, innovative nano-drug delivery systems are being developed to enhance the precision of cancer vaccines and improve the uptake of neoantigens by dendritic cells. These systems include lipid nanoparticles, bacteria-derived outer membrane vesicles, exosomes, and amphiphilic vaccines. The personalized dendritic cell-mimicking nanovaccine, known as the nanoDC vaccine, effectively delivers tumor-associated antigens and promotes immune cell maturation, enhancing the efficacy of cancer vaccines.

Next-generation platforms, such as mRNA and DNA-derived vaccines, are promising due to their cost-effectiveness, safety, high potency, and rapid deployment capabilities. These platforms are particularly relevant for combating complex pathogens with immune evasion capabilities and offer potential solutions for non-infectious diseases. The integration of advanced delivery systems to boost vaccine effectiveness and immune response further enhances the prospects of therapeutic vaccines, making them a significant trend in the market.

Country Insights

The MEA therapeutic vaccines market includes key countries such as Saudi Arabia, South Africa, the UAE, and others. Saudi Arabia is expected to hold the largest market share in 2024, driven by increasing healthcare demands due to the rising prevalence of chronic diseases and government support for biotechnology. According to GLOBOCAN 2020, Saudi Arabia reported approximately 27,885 new cancer cases, with projections indicating this number could rise to 60,429 by 2040. The country's healthcare system is recognizing the need for innovative treatments, including therapeutic vaccines, particularly for specific cancer indications.

As the population ages, with a significant increase in individuals over 60 expected by 2050, there will be a growing demand for healthcare solutions tailored to older adults, who are more susceptible to chronic diseases. The Saudi government's commitment to enhancing healthcare services for the elderly, along with increased healthcare spending, creates a favorable environment for the adoption of innovative vaccine therapies.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Product Code: BMIRE00032093

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Middle East & Africa Therapeutic Vaccines Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Prevalence of Chronic Conditions
- 4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
- 4.2.1 Regulatory Challenges
4.3 Market Opportunities
- 4.3.1 Extending Product Pipeline
4.4 Future Trends
- 4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - Middle East & Africa Market Analysis

5.1 Middle East & Africa Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 Middle East & Africa Therapeutic Vaccines Market Forecast Analysis

6. Middle East & Africa Therapeutic Vaccines Market Analysis - by Product

6.1 Cancer Vaccine
- 6.1.1 Overview
- 6.1.2 Cancer Vaccine: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 infectious Disease Vaccine
- 6.2.1 Overview
- 6.2.2 infectious Disease Vaccine: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
- 6.3.1 Overview
- 6.3.2 Others: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. Middle East & Africa Therapeutic Vaccines Market Analysis - by Technology

7.1 Allogenic Vaccine
- 7.1.1 Overview
- 7.1.2 Allogenic Vaccine: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
- 7.2.1 Overview
- 7.2.2 Autologous Vaccine: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Middle East & Africa Therapeutic Vaccines Market Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
- 8.2.1 Overview
- 8.2.2 Clinics: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Middle East & Africa Therapeutic Vaccines Market - Country Analysis

9.1 Middle East & Africa
- 9.1.1 Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Saudi Arabia: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.2.1 Saudi Arabia: Middle East & Africa Therapeutic Vaccines Market Share - by Product
    - 9.1.1.2.2 Saudi Arabia: Middle East & Africa Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.2.3 Saudi Arabia: Middle East & Africa Therapeutic Vaccines Market Share - by End User
  - 9.1.1.3 South Africa: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.3.1 South Africa: Middle East & Africa Therapeutic Vaccines Market Share - by Product
    - 9.1.1.3.2 South Africa: Middle East & Africa Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.3.3 South Africa: Middle East & Africa Therapeutic Vaccines Market Share - by End User
  - 9.1.1.4 United Arab Emirates: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.4.1 United Arab Emirates: Middle East & Africa Therapeutic Vaccines Market Share - by Product
    - 9.1.1.4.2 United Arab Emirates: Middle East & Africa Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.4.3 United Arab Emirates: Middle East & Africa Therapeutic Vaccines Market Share - by End User
  - 9.1.1.5 Rest of Middle East & Africa: Middle East & Africa Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Therapeutic Vaccines Market Share - by Product
    - 9.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Dendreon
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 BioNTech SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck & Co Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Amgen Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Transgene SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 THERAVECTYS SA
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 CureVac SE
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms